Results 201 to 210 of about 48,191 (258)
Some of the next articles are maybe not open access.
Continuum, 2006
To discuss the clinical, laboratory, and histopathologic features and presumed pathogenic mechanisms of the four major categories of idiopathic inflammatory myopathy, namely dermatomyositis, polymyositis, immune-mediated necrotizing myopathy, and inclusion body myositis.Dermatomyositis, polymyositis, necrotizing myopathy, and inclusion body myositis ...
Anthony A, Amato, Steven A, Greenberg
openaire +4 more sources
To discuss the clinical, laboratory, and histopathologic features and presumed pathogenic mechanisms of the four major categories of idiopathic inflammatory myopathy, namely dermatomyositis, polymyositis, immune-mediated necrotizing myopathy, and inclusion body myositis.Dermatomyositis, polymyositis, necrotizing myopathy, and inclusion body myositis ...
Anthony A, Amato, Steven A, Greenberg
openaire +4 more sources
Acta Clinica Belgica, 2004
Primary myositis (or inflammatory myopathies) comprises three main groups of diseases, based on clinical and immunohistochemical characteristics: polymyositis (PM), dermatomyositis (DM) and inclusion body myositis. Their clinical presentation and course are disparate, but a common characteristic is immune dysfunction-related inflammation of the ...
Patrick M., Grogan, Jonathan S., Katz
openaire +5 more sources
Primary myositis (or inflammatory myopathies) comprises three main groups of diseases, based on clinical and immunohistochemical characteristics: polymyositis (PM), dermatomyositis (DM) and inclusion body myositis. Their clinical presentation and course are disparate, but a common characteristic is immune dysfunction-related inflammation of the ...
Patrick M., Grogan, Jonathan S., Katz
openaire +5 more sources
Rivista di neurologia, 1988
The inflammatory myopathies are a heterogeneous group of disorders with recent evidence demonstrating differences in clinical features, pathologic changes, pathogenesis, and response to therapy. The inflammatory myopathies generally produce predominantly proximal, symmetric muscle weakness and wasting. Additional criteria for diagnosis include elevated
Scoppetta C. +4 more
openaire +5 more sources
The inflammatory myopathies are a heterogeneous group of disorders with recent evidence demonstrating differences in clinical features, pathologic changes, pathogenesis, and response to therapy. The inflammatory myopathies generally produce predominantly proximal, symmetric muscle weakness and wasting. Additional criteria for diagnosis include elevated
Scoppetta C. +4 more
openaire +5 more sources
Current Opinion in Neurology, 1996
As well as myositis caused by infectious agents, there is a spectrum of inflammatory myopathies representing diseases with autoimmune response. Subtypes differing in clinical features and morphological characteristics have been described. This review will emphasize new advances and recent efforts to identify pathogenetic mechanisms and immunological ...
D S, Tews, H H, Goebel
openaire +2 more sources
As well as myositis caused by infectious agents, there is a spectrum of inflammatory myopathies representing diseases with autoimmune response. Subtypes differing in clinical features and morphological characteristics have been described. This review will emphasize new advances and recent efforts to identify pathogenetic mechanisms and immunological ...
D S, Tews, H H, Goebel
openaire +2 more sources
Idiopathic Inflammatory Myopathies
Indian Journal of Pediatrics, 2023Idiopathic inflammatory myopathies (IIMs) are a diverse group of diseases characterized by proximal muscle weakness and inflammation in skeletal muscle. Phenotypically, the subtypes include dermatomyositis, polymyositis, inclusion body myositis, and amyopathic dermatomyositis. The most common IIM in children is juvenile dermatomyositis (JDM).
Suma Balan, Sumanth Madan
openaire +2 more sources
Current Treatment Options in Neurology, 2011
The mainstay of treatment for the idiopathic inflammatory myopathies currently and traditionally has been therapeutics aimed at suppressing or modifying the immune system. Most therapies being used are directed towards polymyositis (PM) and dermatomyositis (DM), as there is yet to be efficacious treatment of any kind for inclusion body myositis (IBM ...
B Jane, Distad +2 more
openaire +2 more sources
The mainstay of treatment for the idiopathic inflammatory myopathies currently and traditionally has been therapeutics aimed at suppressing or modifying the immune system. Most therapies being used are directed towards polymyositis (PM) and dermatomyositis (DM), as there is yet to be efficacious treatment of any kind for inclusion body myositis (IBM ...
B Jane, Distad +2 more
openaire +2 more sources
Continuum, 2022
This article outlines the salient clinical, serologic, electrophysiologic, imaging, and histopathologic findings and treatment options for the idiopathic inflammatory myopathies, including those related to immune checkpoint inhibitors and SARS-CoV-2.The classification of idiopathic inflammatory myopathies has improved with the integration of myositis ...
openaire +2 more sources
This article outlines the salient clinical, serologic, electrophysiologic, imaging, and histopathologic findings and treatment options for the idiopathic inflammatory myopathies, including those related to immune checkpoint inhibitors and SARS-CoV-2.The classification of idiopathic inflammatory myopathies has improved with the integration of myositis ...
openaire +2 more sources
Best Practice & Research Clinical Rheumatology, 1995
New information regarding myositis specific autoantibodies, histopathologic analysis of muscle biopsy specimens, and immunogenetic features of the different serologic subsets of disease has greatly increased our understanding of the pathogenesis of the inflammatory myopathies.
C V, Oddis, T A, Medsger
openaire +2 more sources
New information regarding myositis specific autoantibodies, histopathologic analysis of muscle biopsy specimens, and immunogenetic features of the different serologic subsets of disease has greatly increased our understanding of the pathogenesis of the inflammatory myopathies.
C V, Oddis, T A, Medsger
openaire +2 more sources
Current Treatment Options in Neurology, 1999
Patients with polymyositis or dermatomyositis should be treated with prednisone (approximately 1 mg/kg/d) for an initial period of 4 to 6 weeks. Once improvement occurs, the dose should be tapered and converted to an alternate-day regimen, which should be continued for at least 12 months.
, Mastaglia, , Phillips, , Zilko
openaire +2 more sources
Patients with polymyositis or dermatomyositis should be treated with prednisone (approximately 1 mg/kg/d) for an initial period of 4 to 6 weeks. Once improvement occurs, the dose should be tapered and converted to an alternate-day regimen, which should be continued for at least 12 months.
, Mastaglia, , Phillips, , Zilko
openaire +2 more sources
Autoantibodies in Inflammatory Myopathies
The American Journal of the Medical Sciences, 2000Abstract A variety of antibodies directed against cellular constituents, some nuclear and others cytoplasmic, have been reported in patients with inflammatory myopathies; however, it remains uncertain what role, if any, they play in the pathogenesis of these conditions.
Garleep, M.J., Mastaglia, F.L.
openaire +2 more sources